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Mevalonate kinase deﬁciency (MKD) is a severe autoinﬂammatory disease caused by recessive mutations in MVK resulting in
reduced function of the enzyme mevalonate kinase, involved in the cholesterol/isoprenoid pathway. MKD presents with periodic
episodes of severe systemic inﬂammation, poor quality of life, and life-threatening sequelae if inadequately treated. We report the
case of a 12-year-old girl with MKD and severe autoinﬂammation that was resistant to IL-1 and TNF-α blockade. In view of this,
she commenced intravenous tocilizumab (8mg/kg every 2 weeks), a humanised monoclonal antibody targeting the IL-6 receptor
(IL-6R) that binds to membrane and soluble IL-6R, inhibiting IL-6-mediated signaling. She reported immediate cessation of fever
and marked improvement in her energy levels following the ﬁrst infusion; after the ﬁfth dose, she was in complete clinical and
serological remission, now sustained for 24 months. *is is one of the ﬁrst reported cases of a child with MKD treated successfully
with tocilizumab and adds to the very limited experience of this treatment for MKD. IL-6 blockade could therefore be an
important addition to the armamentarium for the treatment of this rare monogenic autoinﬂammatory disease.
1. Introduction
Mevalonate kinase deﬁciency (MKD) is a rare autosomal
recessive autoinﬂammatory disease caused by mutations in
MVK, causing loss of function of the enzyme mevalonate
kinase (MVK). Broadly, two clinical phenotypes are rec-
ognized that vary in severity as determined by the level of
residual enzyme activity. *e milder phenotype of MKD is
a periodic fever syndrome characterized by frequent epi-
sodes of fever typically lasting 3–7 days, abdominal pain,
lymphadenopathy, inﬂammatory eye disease, rashes, and
arthralgia [1] and typically associated with intracellular
MVK activity greater than 1% [2]. *e more severe phe-
notype is mevalonic aciduria (MA), usually associated with
MVK enzyme activity less than 0.5%. MA may result in
a high rate of stillbirth; survivors present soon after birth
with severe systemic inﬂammation, facial dysmorphism,
severe failure to thrive, developmental delay, seizures, and
hepatic involvement [3]. Worldwide, approximately only
300 patients with MKD have been reported [4], including
a recent large series from Europe [1].
*e pathophysiology of autoinﬂammation in MKD is
poorly understood and is suggested to occur as a result of
loss of synthesis of isoprenoid lipids downstream of MVK
[5], in particular geranylgeranyl diphosphate. *is latter is
necessary for prenylation (the addition of a hydrophobic
compound) of small GTPases, the loss of which causes
activation of the inﬂammasome and release of IL-1β [6].
More recent studies have indicated a central role for the
pyrin inﬂammasome as the driver of autoinﬂammation in
MKD [7]. *ere is an inverse relationship between RhoA
activation and activation of the pyrin inﬂammasome: RhoA
activation induces downstream kinases, pyrin phosphory-
lation, and inhibitory binding of phosphorylated pyrin by
14-3-3 proteins [7]. In MKD, deﬁcient geranylgeranylation
of RhoA renders it inactive. *is is because RhoA activation
is dependent on its translocation to the plasma membrane,
and this membrane targeting of RhoA is dependent on
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geranylgeranylation at its C-terminus [7]. Since ger-
anylgeranyl pyrophosphate, the substrate of geranylger-
anylation, is a product of the mevalonate pathway, loss-of-
function mutations of MVK results in depletion of ger-
anylgeranyl pyrophosphate, failure of Rho membrane
binding, and thus persistent RhoA inactivation and con-
sequently pyrin activation which induces IL-1β over-
production in myeloid cells [7, 8]. *us mutations of MVK
lead to release of the normal, constitutive tonic inhibition of
the pyrin inﬂammasome and excess IL-1 production [7].
Consequently, attempts to treat MKD have mainly fo-
cused on IL-1 blockade, as reﬂected in recent international
expert consensus guidance [9]. In fact, therapeutic success
with IL-1 blockade is at best modest. For anakinra
(recombinant interleukin-1 receptor antagonist, blocking
IL-1β and IL-1α), a retrospective series [10] reported only
30% complete remission, and 70% partial remission in
patients with MKD treated with daily anakinra. Canaki-
numab, a monoclonal antibody against IL-1β, appears to
have superior eﬃcacy to anakinra in retrospective studies,
with up to half of patients achieving complete response
[10–12]. A major prospective randomised controlled trial of
canakinumab (150mg monthly) for MKD has reported that
35% met a deﬁnition of response at 16 weeks; and 45% had
a physician global assessment of <2/10 [13]. Since it is now
increasingly apparent that MKD is in fact a multicytokine-
driven disease, with involvement of other proinﬂammatory
cytokines including IL-6 and tumour necrosis factor-α
(TNF-α) [14, 15], this somewhat limited eﬃcacy of IL-1
blockade is perhaps unsurprising. It is thus clear that whilst
IL-1 blockade may be useful in some patients with MKD,
alternative treatments for those who fail to respond ade-
quately to IL-1 blockade are urgently required.
Tocilizumab is a humanised, monoclonal, antihuman IL-
6 receptor (IL-6R) antibody that binds to membrane and
soluble IL-6R, inhibiting IL-6-mediated signaling [16].
Tocilizumab binds to soluble IL-6R present in serum and
joint ﬂuid as well as membrane-bound IL-6R expressed on
the surface of cells, leading to inhibition of receptor-
mediated IL-6 signaling and suppression of several physi-
ological roles of IL-6 [16, 17]. Experience of using tocili-
zumab for the treatment of MKD is limited, with (to date)
only six cases reported. We therefore add to these limited
data describing a child with MKD who was successfully
treated with tocilizumab having failed other treatments and
review the literature regarding IL-6 blockade in MKD.
2. Case Presentation
We present the case of a twelve-year-old girl originally from
the Faroe Islands with compound heterozygotic MKD (p.
V377I/c.417insC), who ﬁrst presented with symptomatic
periodic fever attacks from the age of 3 months. *ese
presented as recurrent episodes of fever (39–41°C) without
infectious cause, occurring once or twice monthly, associ-
ated with rigors, pallor, fatigue, lymphadenopathy (inguinal,
axillary, and intra-abdominal), abdominal pain, oral ul-
ceration, and arthralgia/myalgia of the lower limbs. Attacks
lasted between 3 and 7 days and were accompanied by very
high acute phase responses (C reactive protein [CRP] typ-
ically greater than 100mg/L). Attacks were also triggered by
vaccinations. Her past medical history included an episode
of Stevens–Johnson syndrome in response to penicillin at
the age of three years and appendectomy aged 7 years of
a normal appendix. She was referred to us in London at the
age of 12 years. At that time, she was receiving the anti-
TNFα agent etanercept, which she had been on for the
previous 34 months. She had at best only partial response to
etanercept in terms of attack severity and duration, but was
still missing 100 days per year of school because of attacks
which occurred twice a month, lasting for 3 days. In ad-
dition, despite etanercept, her inﬂammatory markers
remained signiﬁcantly raised between attacks: CRP 82mg/L
(reference range [RR]< 10); serum amyloid A (SAA)
1310mg/L (RR< 10), indicative of severe systemic in-
ﬂammation in-between attacks and signiﬁcant risk of re-
active AA amyloidosis. Anakinra (2mg/kg/day;
recombinant interleukin-1 receptor antagonist) had also
been tried previously, but was complicated both by a severe
skin rash and also by the worst disease ﬂare she had ever
experienced; hence after four weeks, this was discontinued.
Following a six-week washout period from the etanercept
(during which she suﬀered one severe attack), in December
2015 she started intravenous tocilizumab 8mg/kg every 2
weeks.
After one dose of tocilizumab, her CRP and ESR both
rapidly normalised (Figure 1(a)). She had one minor attack
with minor, short-lived ﬂeeting rash, but no fever after the
ﬁrst dose. Since normalisation of CRP is a well-known eﬀect
of tocilizumab and may occur without necessarily any true
improvement in clinical disease activity, we also pro-
spectively used a physician global assessment of disease
activity using a 0 to 10 scale, 0 indicating no disease activity
and 10 indicating severe disease activity (Figure 1(a)), and
change in haemoglobin, white cell count, and platelets
(Figure 1(b)) as adjunctive laboratory indicators of suc-
cessful treatment. In addition, the patient reported signiﬁ-
cant improvement even after a single dose of tocilizumab,
with improved energy levels, reduction in pain, and im-
provement in oral ulceration. She was also able to return to
full-time school.
*is excellent clinical and serological response has been
sustained for more than 24 months. *ere have been no
reported adverse events. *e patient was switched to weekly
subcutaneous tocilizumab at 162mg in June 2016 for ease of
administration and reduction in hospital attendances. A year
since that change, the patient has had several short-lived
ﬂares lasting 1–3 days associated with fever, adenitis, and
mouth blistering, but she has not required prednisolone as
before and overall expressed a preference for the sub-
cutaneous route as it was associated with improved quality of
life despite the breakthrough fever attacks.
3. Discussion
*ere is no deﬁnitive treatment for MKD, and the current
rationale for treatment is based on anecdotal case reports,
retrospective series, and a limited (albeit increasing)
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knowledge regarding the pathogenesis of autoinﬂammation
inMKD.*e European project, Single Hub and Access point
for pediatric Rheumatology in Europe (SHARE), was
launched to address this important unmet clinical need and
provided a systematic literature review and expert consensus
for the treatment of MKD and other autoinﬂammatory
diseases [9]. It is currently suggested that patients withMKD
may beneﬁt from treatment with NSAIDs, steroids, and
biologics, particularly IL-1 blockade or etanercept. Fur-
thermore, the SHARE guidance emphasizes that statins and
colchicine are not eﬀective in MKD [9]. Upon failure of IL-1
blockade and etanercept, IL-6 blockade should be the next
biologic instigated, before considering haematopoietic stem
cell transplantation (HSCT) [9], although data supporting
the use of tocilizumab inMKD are very limited. As such, our
case represents (to the best of our knowledge) only the
seventh subject with MKD treated with tocilizumab. *e
eﬃcacy we observed was immediate, dramatic, and sustained
over 24 months. *is suggests that IL-6 blockade should be
given more consideration in patients with MKD, especially
after failure of IL-1 blockade is demonstrated.
*e biggest series of patients with MKD was recently
described from the Eurofever registry [1] providing addi-
tional, albeit retrospective data regarding the treatment of
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Figure 1: (a) Change in clinical disease activity inﬂammatory markers in response tocilizumab. Note. PGA: physician global assessment,
0–10, 0 indicating absence of disease activity and 10 indicating severe disease. ESR: erythrocyte sedimentation rate. CRP: C reactive protein.
PGA fell from 8/10 immediately before the ﬁrst tocilizumab infusion to 1/10 when assessed immediately prior to the next infusion 2 weeks
later. *is excellent clinical and serological response has been sustained for 24 months. (b) Change in haemoglobin, total white cell count,
and platelet count in response to tocilizumab. Black arrow shows date of ﬁrst dose of tocilizumab.
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MKD. Of note, in that series, 27/114 patients received
anakinra: 6/28 (22%) were reported as complete responders;
18/27 (67%) were partial responders; and 11% had no re-
sponse to anakinra. Anakinra doses are not described in
detail in this report, but are likely to be an important factor
inﬂuencing this (at best) modest eﬃcacy [18]. Canakinumab
was given to 5/114 patients and resulted in complete re-
mission in 4/5, with a partial response in the remaining
subject [10]. Etanercept was used in 27/114 patients and had
a beneﬁcial eﬀect in 16/27 patients (59%), of whom only two
(7%) had a complete response [10]. Eleven/27 patients (41%)
failed to respond to etanercept [10]. Of note, only 2 patients
with severe MKD received tocilizumab, but the treatment
responses are not described in any detail in this series [10].
Whilst expert consensus places tocilizumab as an important
third-line biologic treatment for MKD [9], there have only
been six MKD cases treated with this agent reported
worldwide [15,19–21]. *e details of these reports are
summarized in Table 1.
*e pathogenesis of autoinﬂammation in MKD is poorly
understood although recent studies have emphasized that,
unlike cryopyrin-associated periodic fever syndromes
(CAPS; a purely IL-1-driven autoinﬂammatory disease),
MKD is probably a multicytokine-driven monogenic
autoinﬂammatory disease [2, 5, 15]. One mechanistic model
of inﬂammation in MKD is that of enhanced IL-1β release as
a result of decreased Rho/Rac GTPase prenylation, partic-
ularly in hyperthermic conditions [5]. Stoﬀels et al., how-
ever, observed an increased cytokine response from cells
from MKD patients speciﬁc for TLR4, TLR2, and NOD2
stimulation, which included not only IL-1β, but also IL-1α,
TNFα, and IL-6 [15]. Based on this observation, they
questioned whether or not IL-1β is the central driving cy-
tokine in the pathogenesis of MKD. Since they also observed
excessive caspase-1 protein in leucocytes from MKD pa-
tients, they postulated that this could provide an explanation
as to why these cells are more easily triggered to secrete IL-
1β, but emphasized also that other proinﬂammatory cyto-
kines are involved. *ey concluded that this could account
for the fact that not all patients respond to blockade of IL-1,
as emphasized by the aforementioned results of the only
randomised controlled trial published to date [13]. *ese
observations, and the emerging (albeit limited) clinical ex-
perience of IL-6 blockade in MKD (Table 1), argue strongly
for consideration of IL-6 blockade in MKD, particularly for
those who fail to respond adequately to IL-1 blockade [15],
but perhaps also for a clinical trial exploring dosing and
eﬃcacy of tocilizumab as ﬁrst-line choice of biologic for
Table 1: Previous reports of tocilizumab for the treatment of MKD.
Shendi et al. (n� 1)
[19]
Stoﬀels et al. (n� 2)
[15] Lane et al. (n� 2) [20]
Muster et al. (n� 1)
[21]
Patient 1 2 3 4 5 6
TOC dose (mg/kg)
and route of
administration
7 IV 8 IV 8 IV 8 IV 8 IV 8 IV
Frequency of
administration
(weeks)
4 4 4 4 4 4
Age (range), years at
onset of TOC 13
Not
described
Not
described 24 13 36
Treatment prior to
TOC
COL
ANA ANA
ANA
ETA
NSAID
PRED
ETA
SIMVA
ETA ANAANA
Duration of
treatment (months) 20 5 5 24 13 48–60
Outcome
Clinical CR CR CR CR PR
Serological CR Notdescribed PR CR —
Adverse events URTI Notdescribed
Not
described Not described Not described
Comments
CR at dose of 8mg/kg
but due to adverse
events dose reduced,
ultimately with stable
clinical and serological
status on 7mg/kg IV
every 4 weeks
— —
MKD complicated by
AA amyloidosis.
Remained on therapy
with PRED
0.5mg/kg/day
Stabilized on
monotherapy
with TOC
After starting TOC,
average hospital
admissions dropped
11/yr to 3/yr
TOC given in
combination with
IVMP for ﬁrst 3 yrs
then as monotherapy
IV: intravenous; COL: colchicine; PRED: prednisolone; ETA: etanercept; ANA: anakinra; NSAID: nonsteroidal anti-inﬂammatory drug; SIMVA: simvastatin;
CR: complete response; PR: partial response; URTI: upper respiratory tract infection; TOC: tocilizumab; yrs: years.
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MKD. From a practical perspective, tocilizumab is signiﬁ-
cantly cheaper than canakinumab and avoids the need for
daily injections as is the case of anakinra.
*e dose and route of administration of tocilizumab for
MKD has varied across the published reports (Table 1).
Shendi et al. [19] used tocilizumab at an intravenous dose of
8mg/kg, every four weeks. *is is the NICE approved dose
for the treatment of rheumatoid arthritis [22] and for some
forms of JIA in children weighing ≥30 kg [23]. *is patient
went into remission with normalisation of inﬂammatory
markers, but had recurrent upper respiratory tract infections
(well described with tocilizumab) [24] necessitating a 50%
dose reduction. *is lower dose was inadequate to control
the MKD however, and was therefore increased again to
7mg/kg four weekly, with reasonable disease control [19].
We did not observe any infections in our patient, who was
treated with 8mg/kg tocilizumab every two weeks (as per
a typical systemic JIA dosing regimen [25]), or latterly whilst
on weekly subcutaneous tocilizumab. Regarding this latter
point, there are no data that suggest any beneﬁt over in-
travenous or subcutaneous administration; clearly sub-
cutaneous administration has potential practical advantages,
such as avoiding the need for hospital admission for in-
travenous administration as was the case for a patient.
In conclusion, we report a dramatic and sustained (24
months) clinical and serological response to tocilizumab in
a 12-year-old child with MKD, which to the best of our
knowledge represents only the seventh patient reported.
Since a recent randomised placebo-controlled clinical trial of
IL-1 blockade has suggested that more than 50% of patients
may fail to respond adequately, we suggest that further
consideration should be given to alternative approaches such
as IL-6 blockade, particularly for those individuals who fail
IL-1 blockade, and especially before considering haemato-
poietic stem cell transplantation as a therapeutic option.
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